After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nyxoah (NYXH – Research Report), Sandoz Group Ltd (SDZXF – Research Report) and Roche Holding ...

Delpharm also signed a 10-year, long-term supply agreement with Sandoz Canada. BOUCHERVILLE — Delpharm is modernizing its injectable manufacturing facility in Boucherville, Quebec, with the help ...

Novartis said this morning that it remains on course to make a decision on the future of its generics business Sandoz by the end of the year, amid signs of a "return towards normal business ...

Novartis’ practice of initiating layoffs as it reworks marketing priorities is nothing new for the company. In November, the Swiss pharma said it would lay off a total of 139 staffers—also in ...

Ryan Sessegnon struck a stunner against his former club as Fulham boosted their hopes of European qualification with a 2-0 win over toothless Tottenham at Craven Cottage to move up to eighth in ...

Rasmus Hojlund and Alejandro Garnacho ended their goal droughts as Manchester United beat Leicester City 3-0 at the King Power Stadium. Hojlund fired his team in front in the first half for his ...

OTC markets allow trading of 12,400 stocks not listed on major exchanges like NYSE. Risks in OTC markets include higher fraud chances, especially on Pink Sheets. OTCQX, OTCQB, and Pink Sheets vary ...

Orthocell (ASX: OCC) has received regulatory approval from Singapore’s Health Sciences Authority to commence regional sales of its dental membrane product Striate+ for use in guided bone and tissue ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

Postmarketing safety monitoring expectations also vary. The differences between the FDA and EMA approval processes for Sandoz’s filgrastim biosimilar highlight these regulatory inconsistencies. The ...